Chemokine receptor CCR5 in interferon-treated multiple sclerosis

F Sellebjerg; Thomas Birk Kristiansen; P Wittenhagen; P Garred; J Eugen-Olsen; J L Frederiksen; Torben Lykke Sørensen

doi:10.1111/j.1600-0404.2007.00826.x

Chemokine receptor CCR5 in interferon-treated multiple sclerosis

F Sellebjerg, Thomas Birk Kristiansen, P Wittenhagen, P Garred, J Eugen-Olsen, J L Frederiksen, Torben Lykke Sørensen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

16 Citationer (Scopus)

Abstract

Udgivelsesdato: 2007-Jun

Originalsprog	Engelsk
Tidsskrift	Acta Neurologica Scandinavica
Vol/bind	115
Udgave nummer	6
Sider (fra-til)	413-8
Antal sider	5
ISSN	0001-6314
DOI	https://doi.org/10.1111/j.1600-0404.2007.00826.x
Status	Udgivet - 2007

Adgang til dokumentet

10.1111/j.1600-0404.2007.00826.x

Citationsformater

@article{4fd7aa9f7c8d40e48084064ff4d4634c,

title = "Chemokine receptor CCR5 in interferon-treated multiple sclerosis",

abstract = "OBJECTIVE: To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta). METHODS: The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta who were followed clinically for 1 year. Cellular CCR5 expression was measured by flow cytometry. RESULTS: Patients with MS had a higher percentage of CCR5-positive monocytes than healthy controls. Increased monocyte expression of CCR5 correlated weakly with an increased short-term relapse risk but there was no relationship between CCR5 Delta32 allele and CCR5 promoter polymorphism genotypes and relapse risk. CONCLUSIONS: The results do not support a major role of CCR5 in the pathogenesis of relapses in MS patients treated with IFN-beta, but it is possible that monocyte CCR5 expression may be used as a marker of disease activity.",

author = "F Sellebjerg and Kristiansen, {Thomas Birk} and P Wittenhagen and P Garred and J Eugen-Olsen and Frederiksen, {J L} and S{\o}rensen, {Torben Lykke}",

year = "2007",

doi = "10.1111/j.1600-0404.2007.00826.x",

language = "English",

volume = "115",

pages = "413--8",

journal = "Acta Neurologica Scandinavica",

issn = "0001-6314",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Chemokine receptor CCR5 in interferon-treated multiple sclerosis

AU - Sellebjerg, F

AU - Kristiansen, Thomas Birk

AU - Wittenhagen, P

AU - Garred, P

AU - Eugen-Olsen, J

AU - Frederiksen, J L

AU - Sørensen, Torben Lykke

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta). METHODS: The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta who were followed clinically for 1 year. Cellular CCR5 expression was measured by flow cytometry. RESULTS: Patients with MS had a higher percentage of CCR5-positive monocytes than healthy controls. Increased monocyte expression of CCR5 correlated weakly with an increased short-term relapse risk but there was no relationship between CCR5 Delta32 allele and CCR5 promoter polymorphism genotypes and relapse risk. CONCLUSIONS: The results do not support a major role of CCR5 in the pathogenesis of relapses in MS patients treated with IFN-beta, but it is possible that monocyte CCR5 expression may be used as a marker of disease activity.

AB - OBJECTIVE: To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta). METHODS: The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta who were followed clinically for 1 year. Cellular CCR5 expression was measured by flow cytometry. RESULTS: Patients with MS had a higher percentage of CCR5-positive monocytes than healthy controls. Increased monocyte expression of CCR5 correlated weakly with an increased short-term relapse risk but there was no relationship between CCR5 Delta32 allele and CCR5 promoter polymorphism genotypes and relapse risk. CONCLUSIONS: The results do not support a major role of CCR5 in the pathogenesis of relapses in MS patients treated with IFN-beta, but it is possible that monocyte CCR5 expression may be used as a marker of disease activity.

U2 - 10.1111/j.1600-0404.2007.00826.x

DO - 10.1111/j.1600-0404.2007.00826.x

M3 - Journal article

SN - 0001-6314

VL - 115

SP - 413

EP - 418

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

IS - 6

ER -